Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief
*Corresponding Author:
Warning: Undefined variable $i in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156
Warning: Undefined variable $for_cr in /efsdata/omicsonline.org/httpdocs/peer-reviewed/abstract-page.php on line 156
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
According to the White House drug policy office, drug-related fatalities increased by 11.4% year-over-year in the first four months of 2020. As opioid overdose deaths skyrocket across the U.S. during the COVID-19 pandemic, emphasis needs to be placed on proactively creating non-opioid solutions for pain relief. Kannalife, Inc., a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, has been working on a non-opioid solution for pain through its laboratory-created cannabidiol (CBD)-like molecule KLS-13019. In research funded by a grant from the National Institutes of Health’s National Institute on Drug Abuse
